QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:BCYC

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

$28.50
-0.37 (-1.28%)
(As of 02/8/2023 05:18 PM ET)
Add
Compare
Today's Range
$28.10
$29.50
50-Day Range
$26.93
$32.90
52-Week Range
$12.08
$51.93
Volume
142,888 shs
Average Volume
229,265 shs
Market Capitalization
$846.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.64

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
84.7% Upside
$52.64 Price Target
Short Interest
Healthy
6.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Bicycle Therapeutics in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$279,441 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.84) to ($4.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

529th out of 1,026 stocks

Pharmaceutical Preparations Industry

251st out of 504 stocks

BCYC stock logo

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

Predict These Market Breakouts with A.I.
We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. pixel
Predict These Market Breakouts with A.I.
We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. pixel
Brokerages Set Bicycle Therapeutics plc (NASDAQ:BCYC) PT at $49.90
See More Headlines
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings
11/03/2021
Today
2/08/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.64
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+84.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-66,820,000.00
Net Margins
-669.65%
Pretax Margin
-681.96%

Debt

Sales & Book Value

Annual Sales
$11.70 million
Book Value
$11.78 per share

Miscellaneous

Free Float
27,017,000
Market Cap
$846.17 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Kevin LeeKevin Lee
    Chief Executive Officer & Executive Director
  • Lee H. KalowskiLee H. Kalowski
    President & Chief Financial Officer
  • Alistair Milnes
    Chief Operating Officer
  • Michael Skynner
    Chief Technology Officer
  • Nicholas KeenNicholas Keen
    Chief Scientific Officer













BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings
or view top-rated stocks.

What is Bicycle Therapeutics' stock price forecast for 2023?

13 brokerages have issued 12 month price targets for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $52.64 in the next year. This suggests a possible upside of 82.6% from the stock's current price.
View analysts price targets for BCYC
or view top-rated stocks among Wall Street analysts.

How have BCYC shares performed in 2023?

Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 2.6% and is now trading at $28.82.
View the best growth stocks for 2023 here
.

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BCYC earnings forecast
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The firm had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative net margin of 669.65% and a negative trailing twelve-month return on equity of 31.56%.

What other stocks do shareholders of Bicycle Therapeutics own?
When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.44%), Harbor Capital Advisors Inc. (0.08%), TD Asset Management Inc (0.08%), AtonRa Partners (0.06%), Simplex Trading LLC (0.00%) and Twelve Points Wealth Management LLC (0.02%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $28.82.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $855.67 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

The company employs 119 workers across the globe.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.

This page (NASDAQ:BCYC) was last updated on 2/8/2023 by MarketBeat.com Staff